

Ref. No: 1431
Date: 06/01/25
Subject: Biologics Rheumatology

REQUEST

Q1. Could you please provide the numbers of patients treated by the rheumatology department (for any condition) in the last 3 months with the following drugs:

- **Abatacept [Orencia]**
- **Adalimumab [Humira]**
- **Adalimumab Biosimilars**
- **Apremilast [Otezla]**
- **Baricitinib [Olumiant]**
- **Bimekizumab [Bimzelx]**
- **Certolizumab [Cimzia]**
- **Etanercept [Enbrel]**
- **Etanercept Biosimilars**
- **Filgotinib [Jyseleca]**
- **Golimumab [Simponi]**
- **Guselkumab [Tremfya]**
- **Infliximab [Remicade]**
- **Infliximab Biosimilars**
- **Ixekizumab [Taltz]**
- **Risankizumab [Skyrizi]**
- **Rituximab [MabThera]**
- **Rituximab Biosimilars**
- **Sarilumab [Kevzara]**
- **Secukinumab [Cosentyx]**
- **Tocilizumab [Ro Actemra]**
- **Tocilizumab Biosimilars**
- **Tofacitinib [Xeljanz]**
- **Upadacitinib [Rinvoq]**
- **Ustekinumab [Stelara]**
- **Ustekinumab Biosimilar**

Q2. Could you please provide the numbers of patients treated for Psoriatic Arthritis ONLY in the last 3 months with the following drugs:

- Abatacept [Orencia]
- Adalimumab [Humira]
- Adalimumab Biosimilars
- Apremilast [Otezla]
- Bimekizumab [Bimzelx]
- Certolizumab [Cimzia]
- Etanercept [Enbrel]
- Etanercept Biosimilars
- Golimumab [Simponi]
- Guselkumab [Tremfya]
- Infliximab [Remicade]
- Infliximab Biosimilars
- Ixekizumab [Taltz]
- Risankizumab [Skyrizi]
- Secukinumab [Cosentyx]
- Tofacitinib [Xeljanz]
- Upadacitinib [Rinvoq]
- Ustekinumab [Stelara]
- Ustekinumab Biosimilar

RESPONSE

Q1.

• Abatacept [Orencia]	72
• Adalimumab [Humira]	47
• Adalimumab Biosimilars	364
• Apremilast [Otezla]	<5
• Baricitinib [Olumiant]	85
• Bimekizumab [Bimzelx]	0
• Certolizumab [Cimzia]	36

· Etanercept [Enbrel]	43
· Etanercept Biosimilars	231
· Filgotinib [Jyseleca]	15
· Golimumab [Simponi]	50
· Guselkumab [Tremfya]	6
· Infliximab [Remicade]	0
· Infliximab Biosimilars	30
· Ixekizumab [Taltz]	7
· Risankizumab [Skyrizi]	0
· Rituximab [MabThera]	0
· Rituximab Biosimilars	35
· Sarilumab [Kevzara]	<5
· Secukinumab [Cosentyx]	62
· Tocilizumab [Ro Actemra]	49
· Tocilizumab Biosimilars	0
· Tofacitinib [Xeljanz]	35
· Upadacitinib [Rinvoq]	22
· Ustekinumab [Stelara]	7
· Ustekinumab Biosimilar	7

Q2

Abatacept [Orencia]	0
Adalimumab [Humira]	<5
Adalimumab Biosimilars	43
Apremilast [Otezla]	<5
Bimekizumab [Bimzelx]	0
Certolizumab [Cimzia]	<5
Etanercept [Enbrel]	<5
Etanercept Biosimilars	24

Golimumab [Simponi]	<5
Guselkumab [Tremfya]	<5
Infliximab [Remicade]	0
Infliximab Biosimilars	5
Ixekizumab [Taltz]	<5
Risankizumab [Skyrizi]	0
Secukinumab [Cosentyx]	19
Tofacitinib [Xeljanz]	<5
Upadacitinib [Rinvoq]	0
Ustekinumab [Stelara]	<5
Ustekinumab Biosimilar	5

<5

Due to the low number of patients receiving the some of the above medications which is less than five for the period, the Trust is withholding the actual number under section 40 – Personal Information of the Freedom of Information Act due to likelihood of identification of the individual(s).

If the requestor or any other member of the general public can, on the balance of probabilities, identify individuals by cross-referencing the anonymised data with other information that was available to them, then the information is personal data and exempt from disclosure under the Act.